CAJ | 학술논문

目的：观察血管内皮生长因子（ VEGF）在40岁以下乳腺浸润性导管癌患者癌组织表达及与淋巴结转移的关系。方法免疫组化技术检测31例≤40岁乳腺浸润性导管癌（实验组）及同期＞40岁83例乳腺浸润性导管癌（对照组） VEGF的表达情况，观察实验组淋巴结转移数与VEGF表达的关系。结果实验组VEGF表达及淋巴结转移率显著高于对照组（ P ＜0.01）；实验组VEGF蛋白表达率与淋巴结转移数目之间存在显著性差异（ P ＜0.05），随着VEGF蛋白表达升高，淋巴结转移数逐渐增加；实验组有淋巴结转移者较无淋巴结转移者原发灶VEGF的表达明显升高（ P ＜0.05）；实验组原发灶与淋巴结转移灶VEGF表达无显著性差异（ P ＞0.05）。结论 VEGF高表达与40岁以下女性乳腺浸润性导管癌淋巴结转移密切相关，可用于指导乳腺癌的治疗及评估预后。
목적：관찰혈관내피생장인자（ VEGF）재40세이하유선침윤성도관암환자암조직표체급여림파결전이적관계。방법면역조화기술검측31례≤40세유선침윤성도관암（실험조）급동기＞40세83례유선침윤성도관암（대조조） VEGF적표체정황，관찰실험조림파결전이수여VEGF표체적관계。결과실험조VEGF표체급림파결전이솔현저고우대조조（ P ＜0.01）；실험조VEGF단백표체솔여림파결전이수목지간존재현저성차이（ P ＜0.05），수착VEGF단백표체승고，림파결전이수축점증가；실험조유림파결전이자교무림파결전이자원발조VEGF적표체명현승고（ P ＜0.05）；실험조원발조여림파결전이조VEGF표체무현저성차이（ P ＞0.05）。결론 VEGF고표체여40세이하녀성유선침윤성도관암림파결전이밀절상관，가용우지도유선암적치료급평고예후。
Objective To investigate the expression of vascular endothelial growth factor ( VEGF) in less than 40 years old women with breast invasive ductal carcinoma and its relationship to lymph node metastasis.Methods The expression of VEGF were detected by immunohistochemistry in 31 cases of experimental group (≤40 years old ) and 83 cases of control group (>40 years old ) , and the relationship between the expression of VEGF and the number of metastatic lymph nodes was also investigated.Results There were higher expression of VEGF and lymph node metastasis rate in experimental group than control group ( P <0.01 ) , and there is statistical significance between expression of VEGF and lymph node metastasis rate in experimental group ( P <0.05 ) , and with the VEGF protein expression increased, the number of lymph node metastasis increased significantly.The positive rate of VEGF in lymph-node-positive group was significantly higher than that in lymph-node-negative group in experimental group ( P <0.05), and their is no statistical significance between lymph node metastasis and primary lesion in experimental group ( P >0.05).Conclu-sion The expression of VEGF is closely related to the lymph node metastasis in breast invasive ductal carcinoma, which might be used to guide breast cancer treatment and assessment of prognosis.